Cempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: CEMP
- CUSIP: 15130J10
- Previous Close: $4.05
- 50 Day Moving Average: $3.22
- 200 Day Moving Average: $12.79
- 52-Week Range: $52,381,000.00 - $2.55
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.98
- P/E Growth: 0.00
- Market Cap: $212.14M
- Outstanding Shares: 52,381,000
- Beta: 0.95
- Net Margins: -678.72%
- Return on Equity: -59.94%
- Return on Assets: -47.76%
Companies Related to Cempra:
- Debt-to-Equity Ratio: 0.05%
- Current Ratio: 10.19%
- Quick Ratio: 10.19%
What is Cempra's stock symbol?
Cempra trades on the NASDAQ under the ticker symbol "CEMP."
Where is Cempra's stock going? Where will Cempra's stock price be in 2017?
17 equities research analysts have issued twelve-month price targets for Cempra's stock. Their predictions range from $2.50 to $32.00. On average, they anticipate Cempra's share price to reach $13.74 in the next twelve months.
When will Cempra announce their earnings?
Cempra is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Cempra stock?
Here are some recent quotes from research analysts about Cempra stock:
- Robert W. Baird analysts commented, "Cempra reported positive Phase 3 data for Taksta (fusidic acid) in acute bacterial skin and skin structure infections (ABSSSI). Taksta showed non-inferiority to linezolid, and was well-tolerated in the study. Given the turbulence in the stock since solithromycin's AdCom and briefing documents, the stock has been up as much as 50% today on the news. However, we continue to believe that the market potential for Taksta is too limited to see value in." (2/24/2017)
According to Zacks Investment Research, "Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. " (1/17/2017)
Cowen and Company analysts commented, "ICPT recently launched Ocaliva for PBC in the US." (6/24/2016)
Needham & Company LLC analysts commented, "Cempra hosted an investor and analyst mtg yesterday in NYC. Several KOLs presented views on target indication Community Acquired Bacterial Pneumonia (CABP) and role of solithromycin (Solithera). High macrolide resistance and consequences of increased use of fluoroquinolones (safety profile and C. difficile) were cited as concerns. KOL panel lamented that physicians are forced to either over-treat (w/ fluoroquinolone) or under-treat (w/ macrolide) and viewed Solithera as a helpful solution. Cempra Phase 3 development program positioned Solithera as an antibiotic with the safety profile of a macrolide and efficacy of a fluoroquinolone. Amongst antibiotics in development, Solithera is uniquely suited for treatment of outpatient respiratory infections. Mgmt guided for pricing to maximize access (less than $400-500 list price) and will negotiate tier II formulary placement ($35 copay). Payers have few concerns w/ acute care products. As a reminder, essentially all other antibiotics in clinical development are geared toward hospital, not retail setting. We expect Cempra to have moderate success in commercializing the drug independently, due to challenges for a biotech company in penetrating urgent and primary care. Key hurdles include creating broad patient and physician awareness of macrolide resistance and fluoroquinolone FDA safety warnings. Although the commercial opportunity is probably larger in hands of Big Pharma, we believe the share price does not reflect what Cempra can accomplish independently." (6/24/2016)
Who owns Cempra stock?
Cempra's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (10.58%), State Street Corp (4.07%), Hodges Capital Management Inc. (1.91%), Renaissance Technologies LLC (1.17%), Palo Alto Investors LLC (0.65%) and Oxford Asset Management (0.52%). Company insiders that own Cempra stock include David Moore, David N Gill, David W Oldach, Dov A Md Goldstein and Garheng Kong.
Who sold Cempra stock? Who is selling Cempra stock?
Cempra's stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, FMR LLC, Gabelli Funds LLC and Gamco Investors INC. ET AL.
Who bought Cempra stock? Who is buying Cempra stock?
Cempra's stock was purchased by a variety of institutional investors in the last quarter, including Hodges Capital Management Inc., State Street Corp, Renaissance Technologies LLC, Oxford Asset Management, Tudor Investment Corp Et Al, Guggenheim Capital LLC, Commonwealth of Pennsylvania Public School Empls Retrmt SYS and Bogle Investment Management L P DE. Company insiders that have bought Cempra stock in the last two years include David Moore, David N Gill and Garheng Kong.
How do I buy Cempra stock?
Shares of Cempra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cempra stock cost?
One share of Cempra stock can currently be purchased for approximately $4.05.